251. Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient
- Author
-
Pithi Chanvorachote, Preedakorn Chunhacha, Virote Sriuranpong, Worrawat Promden, and Sudjit Luanpitpong
- Subjects
Cisplatin ,Cancer Research ,Pathology ,medicine.medical_specialty ,Oncogene ,Pleural effusion ,business.industry ,Cancer ,Articles ,medicine.disease ,respiratory tract diseases ,Oncology ,Antigen ,Cancer stem cell ,Cancer cell ,medicine ,Cancer research ,Lung cancer ,business ,medicine.drug - Abstract
Advances in understanding lung cancer biology and tumor markers aid clinicians in managing the disease. Cancer-associated antigen (CA)125 has garnered increasing attention in lung cancer research and may benefit the treatment and follow-up of this type of cancer. In Thai lung cancer patients, knowledge regarding ethnic differences in cancer cell biology is largely absent. We generated lung cancer cells from the pleural effusion fluids of a Thai patient and designated these as P1 cells. P1 cells were assessed for growth rate, response to chemotherapy, and the presence of tumor markers, in particular CA125 expression. Results of immunofluorescence indicated that P1 cells exhibited strong expression levels of CA125, comparable to that of established H460 lung cancer cells. Furthermore, P1 cells were analyzed for the expression of additional markers. Results revealed that H460 cells exhibited strong immunofluorescent signals from cytokeratin-19 fragments (CYFRA 21-1) and squamous cell carcinoma antigen (SCCA) while P1 presented only CYFRA 21-1 signals. We also found evidence of relative cisplatin resistance in P1 compared to the susceptibility level of established lung cancer cells. Thus, the results and methodology described in this study may aid the development of lung cancer diagnostic and therapeutic approaches and, in particular, advance understanding of ethnic differences.
- Published
- 2012